Cereno Scientific confirms new clinic activated in the Phase II study of drug candidate CS1 in rare disease PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a new clinic has been activated in the ongoing Phase II study of CS1 in the rare disease pulmonary arterial hypertension (PAH). The clinic is located in Austin, Texas, and starts recruiting patients immediately. The Phase II study is now actively running at 10 specialist clinics in the US with yet another new clinic currently in the late-stage start-up process.“We are very pleased to report that we have now activated a new clinic in the